Welcome to our dedicated page for Neutra news (Ticker: NTRR), a resource for investors and traders seeking the latest updates and insights on Neutra stock.
Neutra Corp (NTRR) is a Texas-based innovator in hemp-derived wellness products, including CBD tinctures and clinical-grade topicals. This news hub provides investors and industry observers with essential updates on the company's strategic initiatives and market expansion.
Discover official announcements ranging from product innovations to financial developments, all supporting Neutra Corp's mission to lead in natural wellness solutions. The curated collection includes updates on manufacturing advancements, regulatory compliance progress, and partnership developments within the specialty healthcare sector.
Key focus areas mirror the company priorities outlined in its two-year management plan: direct-to-consumer platform growth, clinical research investments, and educational consulting services expansion. Users will find timely updates on operational milestones including production capacity increases and distribution network enhancements.
Bookmark this page for streamlined access to Neutra Corp's evolving position in the competitive wellness market. Verify time-sensitive details through official SEC filings and corporate communications linked where available.
Neutra Corp. (OTC PINK:NTRR) is advancing its Phase-1 clinical trials to evaluate the effectiveness of hemp-based cannabinoids, specifically CBDa, against COVID-19. Building on prior research from Oregon State University, which indicated that CBDa and CBGa could prevent the virus from entering human cells, Neutra aims to demonstrate these cannabinoids' safety and efficacy in combating the virus. Their subsidiary, VIVIS, has partnered with Mercury Clinical Research for these trials. Neutra is also launching a new gummy product infused with CBDa and CBGa, targeting COVID-related health issues.
Neutra Corp. closed 2021 with record success, achieving significant growth by expanding its product line from 10 to over 75 SKUs, including various hemp-based cannabinoids. The company surpassed its entire 2020 revenue of ~$9,600 in just its first quarter of 2021, bringing in more than $73,000 throughout the year. Key developments included acquiring Deity Wellness and launching new sales initiatives across six states. For 2022, Neutra plans to enhance its e-commerce strategies and marketing efforts while conducting clinical trials with Mercury Clinical Research.
Neutra Corp. (OTC PINK:NTRR) has resumed sales efforts through its subsidiary Deity Wellness after a Texas judge ruled in favor of Delta-8's legality. This ruling has alleviated previous uncertainties, leading to a 66% revenue increase from Q2 to Q3 2021. CEO Sydney Jim reported surging interest in their products, including Delta-8 infused gummies and vape cartridges. The ruling allows Deity Wellness to fulfill pending orders and relaunch promotional initiatives that previously garnered 2,000 early orders.
Neutra Corp. subsidiary VIVIS has signed a letter of intent with Mercury Clinical Research to explore the feasibility of a Phase 1 clinical trial testing hemp-based cannabinoids for treating COVID-19. The trial aims to evaluate CBD's effectiveness against SARS-COVID-2, along with other potential health benefits, such as anti-inflammation and pain management. Neutra CEO, Sydney Jim, expressed optimism about the trial's potential global impact. Previous studies indicate that CBD may reduce SARS-CoV-2 infection rates. As of September 2021, COVID-19 has caused nearly 4.6 million global deaths.
Neutra Corp. subsidiary VIVIS has signed a letter of intent with Mercury Clinical Research for a potential Phase 1 clinical trial to test hemp-based cannabinoids in treating COVID-19. This collaboration aims to explore the efficacy of CBD against SARS-CoV-2, with additional investigations into its potential benefits for inflammation, insomnia, appetite regulation, pain management, and anxiety. The CEO emphasized the significant global impact this research could have, especially given the ongoing pandemic, which has claimed nearly 4.6 million lives worldwide.
Neutra Corp. (OTC PINK:NTRR) announced a new pricing strategy for its VIVIS subsidiary, aimed at making its lab-tested CBD products more affordable amid rising inflation. The decision follows an increase in production capacity following the opening of new facilities in Greater Houston. Additionally, VIVIS is set to launch Labor Day sales to further attract consumers. The company is also expanding its market reach, with products now available at Festival Foods in Wisconsin, Restore Hyper Wellness in Houston, and a potential deal for distribution in Mexico.
Neutra Corp. (OTC PINK:NTRR) has made significant strides in securing distribution channels for its subsidiary VIVIS' CBD products. The company has successfully placed VIVIS' products in Festival Foods, a regional supermarket chain, and is set to announce another distribution partnership soon. Discussions are ongoing with well-known distributors and a Clinical Research company for potential acquisition, which could enhance revenue and support product claims. CEO Sydney Jim noted increasing demand for VIVIS products, signaling potential growth ahead.
Neutra Corp. (OTC PINK:NTRR) announced its CBD products will be available at Festival Foods, starting August 9, 2021, at its flagship store in Onalaska, Wisconsin. This deal is the first step towards expanding its presence in all 34 Festival Foods locations. The initiative is supported by Neutra's national sales team and aims to attract other Midwestern retailers. Additionally, the company reported strong early sales for its Deity Wellness subsidiary's Delta-8 products, reflecting growing interest in CBD offerings.
Neutra Corp. (OTC PINK:NTRR) has announced acceptance of its CBD products in a leading Mid-West grocery chain, with initial sales at the flagship location. This milestone comes as a result of Neutra's national sales team efforts and opens doors for future retail opportunities. Recently, the VIVIS brand also started selling products in Pasadena, Texas, with over 2,000 early orders for Delta-8 gummies and vape cartridges recorded in just two days. The company is focused on expanding its market presence in the thriving CBD sector.
Neutra Corp. (OTC PINK:NTRR) announced its Deity Wellness subsidiary has recorded over 2,000 early orders for Delta-8-infused products within just two days of its launch. This surge follows a recent legislative failure to ban hemp-based THC in Texas, highlighting strong pent-up demand among recreational Delta-8 consumers. CEO Sydney Jim emphasized that the acquisition positions Neutra to capture a competitive edge in the growing Delta-8 market, which appeals to customers seeking enjoyment rather than health benefits, setting it apart from traditional CBD users.
